Polypharmacy and risk of fractures in older adults: A systematic review

J Evid Based Med. 2024 Mar;17(1):145-171. doi: 10.1111/jebm.12593. Epub 2024 Mar 22.

Abstract

Background: Fractures have serious health consequences in older adults. While some medications are individually associated with increased risk of falls and fractures, it is not clear if this holds true for the use of many medications (polypharmacy). We aimed to identify what is known about the association between polypharmacy and the risk of fractures in adults aged ≥65 and to examine the methods used to study this association.

Methods: We conducted a systematic review with narrative synthesis of studies published up to October 2023 in PubMed, Embase, CINAHL, PsychINFO, Cochrane Library, Web of Science, and the grey literature. Two independent reviewers screened titles, abstracts, and full texts, then performed data extraction and quality assessment.

Results: Among the 31 studies included, 11 different definitions of polypharmacy were used and were based on three medication counting methods (concurrent use 15/31, cumulative use over a period 6/31, daily average 3/31, and indeterminate 7/31). Overall, polypharmacy was frequent and associated with higher fracture risk. A dose-response relationship between increasing number of medications and increased risk of fractures was observed. However, only seven studies adjusted for major confounders (age, sex, and chronic disease). The quality of the studies ranged from poor to high.

Conclusions: Polypharmacy appears to be a relevant modifiable risk factor for fractures in older individuals that can easily be used to identify those at risk. The diversity of medication calculation methods and definitions of polypharmacy highlights the importance of a detailed methodology to understand and compare results.

Keywords: fractures; geriatrics; pharmacoepidemiology; polypharmacy; systematic review.

Publication types

  • Systematic Review

MeSH terms

  • Aged
  • Fractures, Bone* / chemically induced
  • Fractures, Bone* / epidemiology
  • Humans
  • Polypharmacy*
  • Risk Factors